Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.
Amgen on Wednesday announced that its phase 3 study involving ABP 959, a biosimilar candidate to eculizumab (Soliris), had met its primary endpoints in the DAHLIA study. The biosimilar is being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other indications.
In its statement, Amgen said that “ABP 959 has the same pharmaceutical form, dosage strength, route of administration, and dosing regimen” as the approved eculizumab in both the United States and the European Union.
Detailed results of this study will be presented at a future medical congress and submitted for publication.
PNH is a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis. This life-threatening disease brings about intravascular hemolytic anemia, bone marrow failure, and thromboembolic episodes. Patients experience arterial and venous thromboembolic episodes, visceral organ damage, rapid deterioration in quality of life, and increased mortality. Eculizumab is a monoclonal antibody that works by binding to a complementary protein to halt the mechanism that drive these effects.
DAHLIA was a phase 3, randomized, double-blind, active-controlled, 2-period crossover study in adult patients with PNH treated with eculizumab for at least 6 months. Patients were randomized 1:1 to receive the biosimilar or reference product in 1 of 2 sequences: (1) the biosimilar was given first, every 14 days for 52 weeks, followed by the reference product, every 14 days for 52 weeks; or (2) treatment followed the same schedule, except the reference product was given first. In the second treatment period, the switch occurred after 26 weeks, at week 79.
Results showed there as no clinically meaningful differences between ABP 959 and Soliris, based on control of intravascular hemolysis and measures of effectiveness at predefined time points, including when patients were switched from one product to the other.
“The safety and immunogenicity profile of ABP 959 was comparable to Soliris,” Amgen said in the statement.
"Today's positive results with ABP 959 demonstrate similar efficacy, safety and immunogenicity as the reference product, further highlighting Amgen's commitment to providing patients with access to high-quality, biologic therapies," said David M. Reese, MD, executive vice president of Research and Development at Amgen. "We look forward to working with regulators to make this potential biosimilar option available to patients."
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.